Humacyte, Inc.
HUMA
$1.26
-$0.05-3.82%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -9.90% | 3,044.86% | |||
| Gross Profit | 9.90% | -3,044.86% | |||
| SG&A Expenses | 1.71% | 27.17% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.09% | 2.49% | |||
| Operating Income | 7.09% | -2.49% | |||
| Income Before Tax | 46.58% | 30.82% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 46.58% | 30.82% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 46.58% | 30.82% | |||
| EBIT | 7.09% | -2.49% | |||
| EBITDA | 7.53% | -2.53% | |||
| EPS Basic | 49.77% | 30.96% | |||
| Normalized Basic EPS | 18.72% | 1.41% | |||
| EPS Diluted | 49.77% | 30.96% | |||
| Normalized Diluted EPS | 18.72% | 1.41% | |||
| Average Basic Shares Outstanding | 6.34% | 0.20% | |||
| Average Diluted Shares Outstanding | 6.34% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||